CAS 148189-70-2
:Votumumab
Description:
Votumumab, identified by the CAS number 148189-70-2, is a monoclonal antibody that has been investigated for its potential therapeutic applications, particularly in the field of oncology. As a monoclonal antibody, it is designed to specifically target and bind to certain antigens present on the surface of cancer cells, thereby facilitating immune-mediated destruction of these cells. Votumumab is characterized by its high specificity and affinity for its target, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. The structure of Votumumab typically includes variable regions that determine its antigen-binding properties and constant regions that mediate immune system interactions. Its development involves sophisticated biotechnological processes, including recombinant DNA technology. While specific clinical data may vary, monoclonal antibodies like Votumumab are generally associated with a favorable safety profile, although potential side effects can occur, necessitating careful monitoring during treatment. Overall, Votumumab represents a significant advancement in targeted cancer therapies, contributing to the growing field of immunotherapy.
Formula:Unspecified
Synonyms:- OncoSPECT
- Votumumab
- Immunoglobulin G 3 (human monoclonal 88BV59 heavy chain anti-human carcinoma-associated antigen), disulfide with human monoclonal 88BV59 κ-chain, dimer
- Immunoglobulin G3, anti-(human carcinoma-associated antigen) (human monoclonal 88BV59 γ3-chain), disulfide with human monoclonal 88BV59 κ-chain, dimer
- 88BV59
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 1 products.
